Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing combination chemotherapy for rheumatoid arthritis

D E Furst1

  • 1Virginia Mason Research Center, Clinical Research Programs, Seattle, Washington 98111.

Annals of the New York Academy of Sciences
|November 30, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.

Arthritis research & therapy·2025
Same author

The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).

Clinical rheumatology·2019
Same author

Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.

Journal of scleroderma and related disorders·2018
Same author

Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.

Atherosclerosis·2018
Same author

Secular trends in the impact factors of SLE publications over a 45-year period-a systematic review.

Lupus·2018
Same author

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Scandinavian journal of rheumatology·2017

This study presents a rational approach for combining disease-modifying antirheumatic drugs (DMARDs) by considering their mechanisms, kinetics, and toxicities. While promising, this method for selecting drug combinations is not foolproof and requires further refinement.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Drug Development

Background:

  • Selecting effective disease-modifying antirheumatic drug (DMARD) combinations is complex.
  • Understanding DMARD mechanisms, pharmacokinetics, and toxicities is crucial for optimizing treatment.
  • Current strategies for combining DMARDs may not always yield optimal outcomes.

Purpose of the Study:

  • To introduce a rational approach for selecting DMARD combinations.
  • To identify non-overlapping DMARD combinations based on their properties.
  • To evaluate the predictive accuracy of this rational approach.

Main Methods:

  • Combining knowledge of DMARD mechanisms of action.
  • Integrating DMARD pharmacokinetic and toxicity profiles.

Related Experiment Videos

  • Identifying combinations with non-overlapping properties.

    • Main Results:

    • The rational approach showed encouraging results in predicting responses.
    • The approach is not infallible, as demonstrated by specific drug combinations.
    • Encouraging results were obtained when comparing predictions to existing studies.

    Conclusions:

    • The presented approach offers a framework for rational DMARD combination selection.
    • Further refinement of rational drug combination strategies is warranted.
    • Continued research aims to improve success rates and reduce costs in testing DMARD combinations.